These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24743279)

  • 21. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Single-dose First-generation 5-HT
    Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
    Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.
    Hesketh PJ; Younger J; Sanz-Altamira P; Hayden M; Bushey J; Trainor B; Krentzin M; Nowd P; Arnaoutakis K; Hesketh AM
    Support Care Cancer; 2009 Aug; 17(8):1065-70. PubMed ID: 19066985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
    Svanberg A; Birgegård G
    Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    He M; Xu R; Liu M; Zhang Y; Yi F; Wei Y; Liu Q; Zhang W
    Ann Palliat Med; 2021 Apr; 10(4):4308-4319. PubMed ID: 33894731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
    Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy.
    Kawazoe H; Motoki Y; Takechi Y; Shishino Y; Ido K; Suemaru K; Araki H
    Methods Find Exp Clin Pharmacol; 2010 Sep; 32(7):499-505. PubMed ID: 21069101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
    Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
    Jordan K; Jahn F; Jahn P; Behlendorf T; Stein A; Ruessel J; Kegel T; Schmoll HJ
    Bone Marrow Transplant; 2011 Jun; 46(6):784-9. PubMed ID: 20838387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.
    Wu CE; Liaw CC
    Support Care Cancer; 2012 Oct; 20(10):2357-61. PubMed ID: 22187110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
    Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
    Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
    Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
    Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
    Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
    J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
    Ito F; Furukawa N
    Support Care Cancer; 2017 Jun; 25(6):1941-1945. PubMed ID: 28160077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.